Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nafcillin Sodium

FDA-approved product (capsule, oral), marketed as Nafcillin Sodium, Nallpen, Nallpen In Plastic Container and 2 more.

Registered studies
19
Lab records
7
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nafcillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF06

Repurposing investigation

Nafcillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA74.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 4 of 7 lab records
Open Nafcillin Sodium in ChEMBL Registered studies below
Show the 7 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nafcillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

    NCT00077675 · start 2004-02

    Registered record
    Registry ID
    NCT00077675
    Conditions
    Infections, Gram-positive Bacterial
    Interventions
    Telavancin; vancomycin or antistaphylococcal penicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-09
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Gram-positive Bacterial
    InterventionTelavancin; vancomycin or antistaphylococcal penicillin
    PhasePhase 2
    Registry statusCompleted

  • Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

    NCT00062647 · start 2003-08

    Registered record
    Registry ID
    NCT00062647
    Conditions
    Gram-Positive Bacterial Infections
    Interventions
    Telavancin; Vancomycin, nafcillin, oxacillin, or cloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-08
    Completion
    2006-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections
    InterventionTelavancin; Vancomycin, nafcillin, oxacillin, or cloxacillin
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

    NCT00061633 · start 2003-06

    Registered record
    Registry ID
    NCT00061633
    Conditions
    Infections, Gram-Positive Bacterial; Abscess; Burns; Cellulitis; Ulcer; Wound Infections
    Interventions
    Telavancin; Vancomycin or antistaphylococcal penicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2004-01
    Enrolment
    169

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Gram-Positive Bacterial; Abscess; Burns; Cellulitis +2 more
    InterventionTelavancin; Vancomycin or antistaphylococcal penicillin
    PhasePhase 2
    Registry statusCompleted

  • Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia

    NCT07186894 · start 2000-01-01

    Registered record
    Registry ID
    NCT07186894
    Conditions
    Bacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    Interventions
    Antistaphylococcal penicillins; Cefazolin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2000-01-01
    Completion
    2026-09-01
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    InterventionAntistaphylococcal penicillins; Cefazolin
    PhaseNot recorded
    Registry statusActive not recruiting